Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045529 | 0.87 | TSHR (0.61) | TSHRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL4527898 | 0.87 | KMT2A (0.49) | TSHRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1126625 | 0.84 | ALDH1A1 (0.49) | TSHRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL970569 | 0.83 | KMT2A (0.45) | TSHRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL31742503 | 0.83 | KMT2A (0.45) | TSHRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1156440 | 0.82 | NR4A2 (0.41) | TSHRKMT2AALDH1A1MAPTLMNA | |
| SCHEMBL969677 | 0.82 | TSHR (0.55) | TSHRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL7439372 | 0.82 | KMT2A (0.61) | TSHRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL12466625 | 0.80 | KMT2A (0.45) | TSHRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL6162557 | 0.80 | SMN1; SMN2 (0.62) | TSHRALDH1A1MAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919904-B2 | Northern-southern route to synthesis of bacteriochlorins | NORTH CAROLINA STATE UNIVERSITY (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919904-B2 | Northern-southern route to synthesis of bacteriochlorins | NORTH CAROLINA STATE UNIVERSITY (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190256521-A1 | NORTHERN-SOUTHERN ROUTE TO SYNTHESIS OF BACTERIOCHLORINS | UNITED STATES DEPARTMENT OF ENERGY | 2019-08-22 | — | — | US | disclosed |
| US-20190256521-A1 | NORTHERN-SOUTHERN ROUTE TO SYNTHESIS OF BACTERIOCHLORINS | UNITED STATES DEPARTMENT OF ENERGY | 2019-08-22 | — | — | US | disclosed |
| WO-2018035281-A1 | NORTHERN-SOUTHERN ROUTE TO SYNTHESIS OF BACTERIOCHLORINS | NORTH CAROLINA STATE UNIVERSITY (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| EP-1669071-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7244733-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7112675-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060128709-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1669071-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1183033-B1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-6982265-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-01-03 | — | — | US | disclosed |
| EP-1183033-A4 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1183033-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071129-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256521-A1 | NORTHERN-SOUTHERN ROUTE TO SYNTHESIS OF BACTERIOCHLORINS | DLD, HCCS, PPIF | TSHR 3314/4885KMT2A 3933/4885MEN1 2209/4885 |
| US-10919904-B2 | Northern-southern route to synthesis of bacteriochlorins | DLD, HCCS, PPIF | TSHR 3314/4885KMT2A 3933/4885MEN1 2209/4885 |
| US-20060128709-A1 | Pyrrolotriazine inhibitors of kinases | FGFR1, FGFR2, ERBB2 | TSHR 1494/4885KMT2A 1516/4885MEN1 4062/4885 |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | FGFR1, FGFR2, ERBB2 | TSHR 1494/4885KMT2A 1516/4885MEN1 4062/4885 |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | VEGFA, PGF, FLT1 | TSHR 1453/4885KMT2A 3738/4885MEN1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.